Enterococcus lactis as Next Generation Probiotics
Creative Biolabs will work with you to speed development and unleash the potential of your Enterococcus lactis (E. lactis)-based drug discovery and development. With our extensive experience and advanced platform, including many E. lactis-associated products, we are driven by science and can solve complex large molecule challenges. We are committed to providing many E. lactis-based next-generation probiotics (NGPs) with high levels of specificity, sensitivity, and lot-to-lot consistency for our worldwide customers.
Introduction to E. lactis
E. Lactis, a member of family Enterococcaceae, is a ubiquitous commensal bacterium that usually exists in pairs or short chains. E. Lactis can grow in low pH, high salt, and high-temperature environment. Previous studies have demonstrated that E. Lactis play a significant role in regulating the metabolism of digestion and intestines. In general, E. Lactis has been broadly used as adjutants and NGP candidates for the prevention and treatment of various human and animal diseases, especially for malignant tumors. Previous studies have indicated that E. lactis can prevent the occurrence of tumors by decreasing the expression level of pro-carcinogenic enzymes, enhancing normal cell proliferation, as well as inhibiting inflammation-associated cell apoptosis. As a consequence, a large group of E. lactis strains has been isolated from different kinds of food and mammal samples, such as raw shrimps, raw milk, and the human gut. Furthermore, most E. lactis strains have been regarded as attractive candidates for developing a new class of live biotherapeutics drugs in cancer therapy.
Fig.1 Enterococcus lactis-based NGPs Services.
E. lactis for Disease Treatment
Recent studies have shown that E. lactis-based NGPs play a critical role in mediating the survival and progression of many human and animal diseases, as well as could provide a novel therapeutic approach. In this condition, a series of E. lactis-based NGPs targeting different kinds of diseases have been generated and widely used for pre-clinical or clinical studies.
Nowadays, Creative Biolabs has established a full range of anti-PDGFR antibody discovery and development services to meet the requirement of our clients based on detailed disease types, especially for cancer therapy. In the past few years of studies, many E. lactis strains, such as 4P3 and IW5, have shown promising results in suppressing the growth of certain pathogenic bacteria and reducing the activity of different cancer cells, including HeLa and AGS. Meanwhile, the safety and biotechnology properties of E. lactis have also been exclusively studied. The data have suggested that several E. lactis strains, like Q1 and 4CP3, can survive in the gastrointestinal tract and no adverse side effect has been observed in preclinical trials. Moreover, many evidence for the therapeutic efficacy of these E. lactis-based strains have also been proved in double-blind randomized clinical trials for treating breast cancer in the human.
Highlights of Our Enterococcus lactis Drug Discovery Services
Creative Biolabs has an entrepreneurial team of highly-skilled and qualified experts in bacterial immunology, biochemistry analysis, and live biotherapeutics drug Discovery. The members have originated from a rich academic research background, bringing their experience into translation. Nowadays, we offer a wide range of E. lactis-based NGP discovery services to relieve our customers from the cumbersome process of drug development.
-
Strain Isolation and Identification
-
Acid and Bile Tolerance Assay
-
Antimicrobial Susceptibility Assay
-
Toxicity Assay
-
Enzyme Activity
-
Apoptosis Assay
With the broadest range of E. lactis studies platforms, we offer custom E. lactis -based NGPs development to accelerate your drug research and disease therapy project. Whether you need any custom E. lactis -based services or help with an E. lactis-based project, take advantage of our expertise and rest assured that your project is in capable hands. For more detailed information, please feel free to contact us or send us an inquiry.
Related Products
|
CAT
|
Product Name
|
Product Overview
|
|
LBST-103FG
|
Enterococcus lactis; 4Du-1
|
Enterococcus lactis is a microaerophile, mesophilic, Gram-positive bacterium that was isolated from excrement of weaned piglets.
|
|
LBST-104FG
|
Enterococcus lactis; ZCYMa05
|
Enterococcus lactis is a microaerophile, mesophilic, Gram-positive bacterium that was isolated from feces of tumor patients.
|
|
LBST-105FG
|
Enterococcus lactis; 20421
|
Enterococcus lactis is a microaerophile, mesophilic, Gram-positive bacterium that was isolated from Yoghurt.
|
|
LBST-106FG
|
Enterococcus lactis; 2007-0-1
|
Enterococcus lactis is a microaerophile, mesophilic, Gram-positive bacterium that was isolated from Yoghurt.
|
|
LBST-107FG
|
Enterococcus lactis; BR-1-16
|
Enterococcus lactis is a microaerophile, mesophilic, Gram-positive bacterium that was isolated from Vinegar.
|
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
